



# City Research Online

## City St George's, University of London

**Citation:** Conway, M. L. & Ctori, I. (2022). Cerebrovascular Function in Migraine Patients during, their Interictal Period, Compared to Normal Healthy Controls. *Journal of Neurosonology and Neuroimaging*, 14(2), pp. 71-77. doi: 10.31728/jnn.2022.00122

This is the published version of the paper.



This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.

**Permanent repository link:** <https://openaccess.city.ac.uk/id/eprint/29582/>

**Link to published version:** <https://doi.org/10.31728/jnn.2022.00122>

**Copyright and Reuse:** Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).

## Cerebrovascular Function in Migraine Patients during, their Interictal Period, Compared to Normal Healthy Controls

Miriam Louise Conway, PhD ; Irene Ctori, PhD 

Optometry & Visual Science, City, University of London, London, UK

**BACKGROUND:** Migraine is a debilitating neurovascular disorder which primarily impacts the working age population. The aim of the study was to determine if transient hemodynamic alterations during each migraine attack translates into cerebrovascular alterations, during migraineurs interictal period. A secondary hypothesis was to determine if there was any relationship between vascular hemodynamics and either the severity or frequency of migraine attacks.

**METHODS:** We recruited 29 volunteers: 13 migraineurs (mean age  $28 \pm 8.8$  years; 12 female and 1 male) and 16 age-matched controls (mean age  $26.6 \pm 6.9$ ; 9 female and 7 male). Volunteers were classified as migraine sufferer or not (control group). All individuals underwent a detailed ophthalmic examination by a qualified optometrist and a Migraine Disability Assessment. Cerebral blood velocity measurements for the Middle Cerebral Artery (MCA) and Vertebral Artery (VA) were obtained using Colour Doppler Imaging using the Hitachi Aloka Noblus ultrasound system. The investigators were blind to the migraine diagnosis.

**RESULTS:** During their interictal period migraineurs appear to have no significant difference in any hemodynamic parameter, for either their MCA and VA, when compared to normal healthy controls. Neither was a significant relationship between Migraine Disability Assessment Scores and any vascular parameter reported.

**CONCLUSION:** This study found nil cerebrovascular alterations which could be measured in migraineurs compared to normal healthy controls, during their interictal period.

*J Neurosonol Neuroimag 2022;14(2):71-77*

**KEY WORDS:** migraine; neurology

**Received:** September 15, 2022

**Revised:** December 7, 2022

**Accepted:** December 7, 2022

**Correspondence:**

Miriam Louise Conway, PhD

Optometry & Visual Science, City,  
University of London, Myddelton  
Street Building, City, University  
of London, Northampton Square,  
London EC1V 0HB, UK

Tel: +44-20-70408392

E-mail: miriam.conway.1@city.ac.uk

### INTRODUCTION

Migraine is a neurological disorder which is often associated with a range of debilitating symptoms. In the under fifties, it is the first cause of worldwide disability with an estimated prevalence of 14.7%.<sup>1</sup> Attacks are most common in the working age population.<sup>2</sup> The fiscal impact of migraine to the UK alone, is conservatively estimated at GBP 3.42 billion a year.<sup>3</sup> Researchers have reported a positive correlation between the frequency of migraine and the levels of depression and anxiety.<sup>4</sup> The prevalence of chronic migraine lies between 1.4 to 2.2%<sup>5</sup> and is highest among middle-aged women.<sup>6</sup> Sufferers are divided

into migraine with or without aura. The lifetime prevalence of migraine without aura is double compared to those with aura.<sup>7</sup> Vascular changes have an important role to play in migraine pathophysiology.<sup>8</sup> Activation of the sensory neurons originating in the trigeminal ganglion, innervate blood vessels from both the meninges and the cerebral arteries via the release of vasoactive neuropeptides.<sup>9</sup> This results in transient vasodilation, activating mechanical and chemical stimulation of the adjacent nociceptors, triggering migraine pain. Triptans are regularly used to treat migraine through vasoconstriction of meningeal vessels, decreased neurogenic inflammation, and reduced central nociception.<sup>10</sup>

Strong significant evidence shows that migraine attacks are accompanied by significant derangements in vascular function.<sup>11-14</sup> The vascular theory states that during the aura phase of a migraine attack, there is an intracranial vasospasm resulting in a reduction in cerebral blood flow which continues to reduce whilst the headache develops.<sup>13</sup> The early vasoconstrictive stage is followed by vasodilation of the meningeal blood vessels,<sup>13</sup> which activates the trigeminal sensory nerves,<sup>15</sup> causing pain. In more recent years there is evidence to suggest that the dilation of vessels, during a migraine attack, does not involve the intracranial vasculature or relate to the pain.<sup>11,12,14</sup> These researchers believe that the vasodilation relates to, the extracranial terminal branches of the external carotid artery which instigates the pain.<sup>12,14</sup> A theory which is further supported by the fact that migraine provoking agents have vascular altering properties and that the most successful medications (ergots and triptans) constrict abnormally dilated vessels.<sup>16</sup>

The prevalence of stroke and vascular disease is higher in patients diagnosed with migraine.<sup>17-19</sup> Some researchers have reported that the risk of stroke is unexpectedly greater in younger female migraineurs.<sup>20,21</sup> Normal tension glaucoma<sup>22</sup> and migraine<sup>23</sup> have a known female predominance. The reason behind this disparity is unknown however, some have postulated that the higher frequency of vasospasm<sup>24,25</sup> and vascular disease<sup>19</sup> found in females, also contributes towards the higher prevalence of normal tension glaucoma and migraine. Cerebral endothelial dysfunction has been documented in patients diagnosed with migraine.<sup>26,27</sup> Vasodilation is endothelial dependent and can be measured via cerebrovascular reactivity. There is significant evidence to suggest that migraineurs have reduced cerebrovascular reactivity (poor auto-regulation), as the majority of studies recorded significantly lower breath holding index when their results were compared against normal healthy controls.<sup>28-32</sup> Investigators have further postulated that reduced cerebrovascular reactivity, particularly in younger migraineurs, might explain in part the implausible relationship between stroke and younger migraineurs.<sup>31</sup> Further clarification however is still desirable as one further study reported contradictory findings.<sup>33</sup>

The primary aim of the study was to determine if there are any vascular alterations in either the Middle Cerebral Artery (MCA) or the Vertebral Artery (VA), during the inter-

ictal period, which could be measured in migraineurs compared to normal healthy controls. A secondary hypothesis was to determine if there was any relationship between vascular hemodynamics, during the interictal period and either the severity or frequency of migraine attacks.

## SUBJECTS AND METHODS

Participants aged between 18 and 45 years old, were recruited from December 2018 to May 2019. Otherwise healthy volunteers diagnosed with migraine and normal healthy controls were included in the study. Participants who were pregnant or presented with any ocular disease were excluded from the study. The study received ethical approval from the appropriate Institutional Review Board (City, University of London's ethics committee, Number Opt/PR/46). Prior to enrolment in the study written informed consent was obtained for all volunteers, following the tenets of the Declaration of Helsinki. An anonymous questionnaire (Supplementary Material) was completed by all volunteers. The questionnaire was developed according to the Headache International Society criteria<sup>34</sup> and included a Migraine Disability Assessment Score (MIDAS). Volunteers were assigned to the control group if they had had less than 3 headaches in the past year and had not experienced a migraine. All volunteers were asked not to intake alcohol or caffeine and confirm that they had not suffered any migraine 24 hours before the test.

The following tests were carried out monocularly by all patients. Best-corrected visual acuity was recorded using a LogMAR chart (Thomson Software Solutions, Hatfield, UK). Ocular axial length was recorded using the Topcon Aladdin Optical Biometer and Corneal Topographer HW 3.0 (Tokyo, Japan), visual fields were examined using the Humphrey Field Analyzer (HFA-3) (Dublin, CA, USA). Objective refraction was carried out and intraocular pressure measurements were taken via the Topcon Auto Kerato-Refracto Tonometer (TRK-2P). Fundus photograph, peripapillary Retinal Nerve Fibre Layer thickness, Retinal Thickness, Ganglion Cell Complex, ranging from the inner-limiting membrane to the inner plexiform layer, and Choroidal Thickness were measured using the *3D OCT-1Maestro*, Topcon, a Spectral Domain OCT (SD-OCT) device.

A different examiner who was an experienced sonog-

rapher (MC) recorded all the vascular measurements. The subject's blood pressure height (cm) and weight (kg) were measured before taking the cerebral blood flow readings. Cerebral blood velocity measurements for the MCA and VA were obtained using Colour Doppler Imaging (CDI) using the Hitachi Aloka Noblus ultrasound system (Tokyo, Japan). Peak Systolic Velocity (PSV), End Diastolic Velocity (EDV), Mean Flow Velocity (MFV), Pulsatility Index (PI) and Resistivity Index (RI) were recorded bilaterally for each examined vessel. The standardised procedure of measuring cerebral blood flow via CDI was used. A Hitachi S211 5-1 MHz was gently applied to our participants trans-temporal and sub-occipital acoustic window while the patients were lying supine on their side and sitting upright on a chair, using a sterile ophthalmic coupling gel. This study has the advantage of ensuring that each investigator was blind to the diagnosis.

## RESULTS

The population consisted of 13 migraine-suffering volunteers (mean age  $28 \pm 8.8$ , 12 female and 1 male) and 16 normal healthy controls (mean age  $26.6 \pm 6.9$ , 9 female and 7 male). Among the 13 participants suffering from migraine: 61.5% (8/13) had migraine with aura; 38.5% (5/13) had migraine with no aura. All data from both the migraine population and the normal healthy controls was initially tested via a Kolmogorov–Smirnov test to determine if the data was normally distributed or not. Some were found to be normally distributed and the others were not. It was therefore necessary to use a combination of independent *t*-tests (parametric) and Mann–Whitney U tests (non-parametric) to investigate whether there was a significant difference between any blood flow parameters in the migraine population, during their interictal period compared to normal healthy controls.

**TABLE 1. Baseline demographic characteristics**

Patient demographics	Migraine (n=13)	Control group (n=16)	<i>p</i> -value
Age (years)	Mean rank=15.38	Mean rank=14.69	0.846*
Gender	Mean rank=17.88	Mean rank=12.66	0.101*
SBP (mmHg)	11.6±1.2	12.3±1.6	0.251
DBP (mmHg)	7.9±1.1	7.7±0.9	0.612
MIDAS score	Mean rank=22.96	Mean rank=8.53	<0.0001*
Headache frequency	Mean rank=22.00	Mean rank=9.31	<0.0001*

Values are presented as mean±standard deviation.

SBP, systolic blood pressure; DBP, diastolic blood pressure; MIDAS, Migraine Disability Assessment Score.

For the Mann–Whitney \* non-parametric analysis, mean rank was used.

**TABLE 2. Comparison of ocular characteristics**

Ocular parameter	Migraine (n=13)	Control group (n=16)	<i>p</i> -value
Visual Acuity right eye (logMar)	-0.02±0.07	-0.07±0.09	0.125
Visual Acuity left eye (logMar)	-0.04±0.08	-0.07±0.12	0.577
IOP right eye (mmHg)	Mean rank=16.42	Mean rank=13.84	0.423*
IOP left eye (mmHg)	Mean rank=16.00	Mean rank=14.19	0.589*
CCT right eye (µm)	505.62±27.53	512.50±39.22	0.598
CCT left eye (µm)	501.31±26.41	510.38±37.90	0.472
Axial length right eye (mm)	23.69±1.22	24.09±1.34	0.418
Axial length left eye (mm)	23.60±1.23	23.96±1.32	0.451

Values are presented as mean±standard deviation.

IOP, intraocular pressure; CCT, central corneal thickness.

For the Mann–Whitney \* non-parametric analysis, mean rank was used.

No patient had any ocular disease. Additionally, there was no significant difference between the migraine and control group in terms of either gender, distribution of age, systolic or diastolic blood pressure  $p > 0.05$  (Table 1), neither was there a significant difference between all ocular characteristics  $p > 0.05$  (Table 2). Unsurprisingly a significant difference was documented for MIDAS scores and headache frequency between the migraineurs and the normal healthy controls via Mann–Whitney U test  $p < 0.0001$ .

No significant difference between EDV, PSV, MFV, RI & PI and either the VA or MCA between migraineurs and normal healthy controls via an independent  $t$ -test or the appropriate non-parametric equivalent was documented (Tables 3, 4). Finally, a Spearman's Rank order correlation indicated no significant relationship between either MIDAS scores or the frequency of headache over a 3-month period for any of the vascular parameters recorded ( $p > 0.05$  for all).

**TABLE 3. Comparison of vascular parameters between the migraineurs and normal healthy controls for the VA**

Vascular parameters	Migraine (n=13)	Control group (n=16)	$p$ -value
MFV RE VA	33.04±10.63	32.49±8.6	0.24
PSV RE VA	53.61±12.63	54.92±8.24	0.06
EDV RE VA	21.61±7.25	22.16±5.79	0.16
RI RE VA	Mean rank=15.77	Mean rank=14.33	0.68*
PI RE VA	Mean rank=14.85	Mean rank=15.12	0.95*
MFV LE VA	30.24±8.24	29.55±8.72	0.97
PSV LE VA	50.38±10.25	55.24±9.59	0.62
EDV LE VA	20.85±9.85	21.53±6.64	0.44
RI LE VA	Mean rank=15.23	Mean rank=14.81	0.91*
PI LE VA	Mean rank=13.50	Mean rank=16.22	0.40*

Values are presented as mean±standard deviation.

VA, vertebral artery; MFV, mean flow velocity; RE, right eye; PSV, peak systolic velocity; EDV, end diastolic velocity; RI, resistivity index; PI, pulsatility index; LE, left eye.

For the Mann–Whitney \* non-parametric analysis, mean rank was used.

**TABLE 4. Comparison of vascular parameters between the migraineurs and normal healthy controls for the MCA**

Vascular parameters	Migraine (n=13)	Control group (n=16)	$p$ -value
MFV RE MCA	58.97±11.69	61.49±10.34	0.87
PSV RE MCA	93.16±18.11	95.26±11.36	0.33
EDV RE MCA	39.10±11.19	41.20±8.81	0.62
RI RE MCA	Mean rank=14.08	Mean rank=15.75	0.62*
PI RE MCA	0.93±0.21	0.88±0.19	0.94
MFV LE MCA	58.78±12.13	60.28±8.63	0.41
PSV LE MCA	93.36±15.52	93.69±12.13	0.33
EDV LE MCA	40.15±11.19	43.56±8.07	0.08
RI LE MCA	0.57±0.08	0.58±0.14	0.40
PI LE MCA	0.92±0.20	0.79±0.17	0.34

Values are presented as mean±standard deviation.

MCA, middle cerebral artery; MFV, mean flow velocity; RE, right eye; PSV, peak systolic velocity; EDV, end diastolic velocity; RI, resistivity index; PI, pulsatility index; RE, right eye; LE, left eye.

For the Mann–Whitney \* non-parametric analysis, mean rank was used.

## DISCUSSION

Our study reports that migraineurs during their interictal period have no significant difference in any hemodynamic parameter, for either their MCA and VA, when compared to normal healthy controls. A recent meta-analysis also investigated these differences and reported higher PI in the posterior circulation of the migraine population, which was more evident when they included migraineurs diagnosed with aura.<sup>35</sup> The authors documented that the mean resting blood flow velocity was higher in both the anterior and posterior circulation of migraine patients when it was compared against normal healthy controls. Closer inspection of their analysis reveals that although the study was extremely thorough in carrying out their systematic literature review. The researchers appear to have counted the data from several studies more than once and in some occasions up to four times. It is likely that this duplication of the data, skewed their results and artificially inflated precision, possibly leading to false conclusions.<sup>36</sup> Their justification for dividing cerebrovascular functions into anterior and posterior circulations could also be made clearer. Closer evaluation of their forest plots suggests that the results from individual studies are quite variable, as opposing findings with wide confidence intervals are recorded. The literature review states that for the anterior and posterior circulation respectively, 86.7% (26/30) and 81.3% of studies (13/16) studies, found no significant difference between the mean blood velocity in migraineurs when results were compared to normal healthy controls. Conversely, outcomes from their meta-analysis suggests that resting blood velocity is significantly different in both circulations for the migraine population. These findings highlight the fact that double counting, may have led to conflicting views within the review and a false positive conclusion.

There was no relationship between either MIDAS scores or frequency of headache attack and any vascular constraint. Findings either suggest that there are no cerebral blood velocity alterations in migraine patients during an attack free period. An alternative explanation is that the present study did not employ sufficient numbers to detect these subtle differences. Recent evidence suggests that resting cerebral velocity alterations are at best contradictory, particularly when you have factored in studies which have carried out multiple statistical comparisons.<sup>28,29,32,33</sup>

Failing to correct for multiple comparisons significantly amplifies the probability of reporting a false positive finding. This suggests that this area of research would benefit from another meta-analysis which does not double count their data. The grouping of arteries should also be approached with caution.

In conclusion this study found nil cerebrovascular alterations which could be measured in migraineurs compared to normal healthy controls, during their interictal period. It must however be acknowledged that this study was limited by the small sample size included. A new systematic review and meta-analysis which includes resting and dynamic cerebral alterations in migraine patients compared to normal healthy controls is therefore needed.

## SUPPLEMENTARY MATERIALS

Supplementary materials related to this article can be found online at <https://doi.org/10.31728/jnn.2022.00122>.

### Ethics Statement

The study protocol was approved by the Institutional Review Board (IRB) of City, University of London. IRB No. Opt/PR/46. Written informed consent was obtained from each individual.

### Availability of Data and Material

The data that support the findings of this study are available in the text.

### Acknowledgments

The authors would like to thank Ms Teresa Paz Moraga for her help with the data collection. They would also like to thank Gill Harrison and Alison Harris for their technical support.

### Sources of Funding

We would like to thank City, University of London for their pump prime funds to purchase the transducer.

### Conflict of Interest

No potential conflicts of interest relevant to this article was reported.

## REFERENCES

1. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? *J Headache Pain*. 2018;19:17.
2. World Health Organization. Headache disorders: how common are headaches? [Internet]. 2014 Feb 11 [cited 2022 Mar 17] Available from <https://www.who.int/news-room/questions-and-answers/item/headache-disorders-how-common-are-headaches>.
3. The All-Party Parliamentary Group on Primary Headache Disorders. Headache Disorders-not respected, not resourced. [Internet]. 2018 Jun 4 [cited 2022 Mar 17] Available from <https://documents.pub/document/headache-disorders-not-respected-not-headache-disorders-not-respected.html?page=4>.
4. Zwart JA, Dyb G, Hagen K, Ødegård KJ, Dahl AA, Bovim G, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trøndelag Health Study. *Eur J Neurol*. 2003;10:147-152.
5. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. *Cephalalgia*. 2010;30(5):599-609.
6. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. *Headache*. 2012;52:1456-1470.
7. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. *Int J Epidemiol*. 1995;24:612-618.
8. Charles A. The pathophysiology of migraine: implications for clinical management. *Lancet Neurol*. 2018;17:174-182.
9. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. *J Cereb Blood Flow Metab*. 1999;19:115-127.
10. Goadsby PJ. The pharmacology of headache. *Prog Neurobiol*. 2000;62:509-525.
11. Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, van der Koning P, Larsson HB, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. *Neurology*. 2010;75:1520-1526.
12. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning PV, Larsson HB, et al. Evidence for a vascular factor in migraine. *Ann Neurol*. 2011;69:635-645.
13. Wolff HG, Tunis MM, Goodell H. Studies on headache: evidence of tissue damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. *Trans Assoc Am Physicians*. 1953;66:332-341.
14. Shevel E. The extracranial vascular theory of migraine--a great story confirmed by the facts. *Headache*. 2011;51:409-417.
15. Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. *Ann Neurol*. 2011;69:855-865.
16. Jansen I, Edvinsson L, Mortensen A, Olesen J. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1-like receptor. *Cephalalgia*. 1992;12:202-205.
17. Terwindt GM, Haan J, Ophoff RA, Groenen SM, Storimans CW, Lanser JB, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. *Brain*. 1998;121(Pt2):303-316.
18. Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and hemorrhagic stroke: a meta-analysis. *Stroke*. 2013;44:3032-3038.
19. Sacco S, Ripa P, Grassi D, Pistoia F, Ornello R, Carolei A, et al. Peripheral vascular dysfunction in migraine: a review. *J Headache Pain*. 2013;14:80.
20. Kurth T, Chabriat H, Bousser MG. Migraine and stroke: a complex association with clinical implications. *Lancet Neurol*. 2012;11:92-100.
21. Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Migraine and incidence of ischemic stroke: a nationwide population-based study. *Cephalalgia*. 2017;37:327-335.
22. Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. *Am J Ophthalmol*. 2001;131:699-708.
23. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB; AMPP Advisory Group. Cumulative lifetime migraine incidence in women and men. *Cephalalgia*. 2008;28:1170-1178.
24. Gramer G, Weber BH, Gramer E. Migraine and vasospasm in glaucoma: age-related evaluation of 2027 patients with glaucoma or ocular hypertension. *Invest Ophthalmol Vis Sci*. 2015;56:7999-8007.
25. Gasser P, Flammer J. Blood-cell velocity in the nailfold capillaries of patients with normal-tension and high-tension glaucoma. *Am J Ophthalmol*. 1991;111:585-588.
26. Tietjen GE, Herial NA, White L, Utley C, Kosmyrna JM, Khu-

- der SA. Migraine and biomarkers of endothelial activation in young women. *Stroke*. 2009;40:2977-2982.
27. Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN, et al. Decreased number and function of endothelial progenitor cells in patients with migraine. *Neurology*. 2008;70:1510-1517.
28. Silvestrini M, Cupini LM, Troisi E, Matteis M, Bernardi G. Estimation of cerebrovascular reactivity in migraine without aura. *Stroke*. 1995;26:81-83.
29. Yousef SAA, Aidaros MAH, El Sayed MS, Fahmy AA. Transcranial doppler assessment of cerebrovascular reactivity in migraine patients. *Egypt J Hosp Med*. 2021;84:2366-2371.
30. Harris S, Rasyid A. Objective diagnosis of migraine without aura with migraine vascular index: a novel formula to assess vasomotor reactivity. *Ultrasound Med Biol*. 2020;46:1359-1364.
31. Lee MJ, Cho S, Woo SY, Chung CS. Paradoxical association between age and cerebrovascular reactivity in migraine: A cross-sectional study. *J Neurol Sci*. 2019;398:204-209.
32. Akgün H, Taşdemir S, Ulaş ÜH, Alay S, Çetiz A, Yücel M, et al. Reduced breath holding index in patients with chronic migraine. *Acta Neurol Belg*. 2015;115:323-327.
33. Petrušić I, Podgorac A, Radojičić A, Zidverc-Trajković J. Transcranial doppler evaluation of the cerebral vasculature in women patients who have migraine with aura. *Pain Med*. 2020;21:3012-3017.
34. Olesen J. The international classification of headache disorders. *Headache*. 2008;48:691-693.
35. Dzator JS, Howe PR, Wong RH. Profiling cerebrovascular function in migraine: a systematic review and meta-analysis. *J Cereb Blood Flow Metab*. 2021;41:919-944.
36. Senn SJ. Overstating the evidence: double counting in meta-analysis and related problems. *BMC Med Res Methodol*. 2009;9:10.

**SUPPLEMENTARY MATERIAL****Participant Questionnaire**

Dear Participant,

Thank you for participating in this study. The purpose of this research is to investigate changes in ocular structures and ocular and cerebral blood flow within migraine sufferers and non-sufferers. This will allow for a more in-depth understanding of the migraine condition and for better treatments to be designed.

Please complete this questionnaire before you come for your appointment. Be sure to call us as soon as possible if you cannot make your appointment.

Today's date:

Name:

DOB:

Gender:

Email:

Tel:

Address:

1. Have you ever been diagnosed with any of the following conditions?

*(Please tick & give details where applicable)*

- |  |  |  |
|--|--|--|
| <input type="checkbox"/> Asthma/COPD               | <input type="checkbox"/> Renal failure       | <input type="checkbox"/> Ocular Hypertension         |
| <input type="checkbox"/> Arthritis                 | <input type="checkbox"/> High Cholesterol    | <input type="checkbox"/> Optic Neuritis              |
| <input type="checkbox"/> Epilepsy                  | <input type="checkbox"/> High Blood Pressure | <input type="checkbox"/> Cataract                    |
| <input type="checkbox"/> Headaches                 | <input type="checkbox"/> Low Blood Pressure  | <input type="checkbox"/> Ocular Surface Disorder     |
| <input type="checkbox"/> Migraines                 | <input type="checkbox"/> Depression          | <input type="checkbox"/> Lazy eye                    |
| <input type="checkbox"/> Heart Disease             | <input type="checkbox"/> Anaemia             | <input type="checkbox"/> Squint operation            |
| <input type="checkbox"/> Vasculitis                | <input type="checkbox"/> Diabetes            | <input type="checkbox"/> Inherited Retinal Disease   |
| <input type="checkbox"/> Thyroid Disease           | <input type="checkbox"/> Glaucoma            | <input type="checkbox"/> Blindness/Partial Blindness |
| <input type="checkbox"/> Other Please give details |  |  |

2. When were you first diagnosed with this condition?

*Please give details*

3. Have any of your first-degree relatives experienced any of the aforementioned conditions? Yes  No

*If yes, please give details*

4. Have you ever had surgery? Yes  No

*If yes, please give details*

5. Are you taking medication? Yes  No

*If yes, please list any medication you are currently taking*

6. Are you taking vitamins or supplements? Yes  No

*If yes, please give details*

7. Do you smoke? Yes  No  If yes, how many cigarettes per day

8. Do you wear spectacles or contact lenses? Yes  No

If yes, how would you describe your vision wearing them?


- Good / perfect       Moderate       Poor

9. Could you please tell us which of the following best describes you?

- Asian
- Black/African
- Caucasian
- Hispanic/Latino
- Native American
- Pacific Islander
- Prefer not to answer
- Other: *Please give details*

10. If female, Are you pregnant? Yes  No

If no, please give details of the menstrual cycle you will be at the appointment date:



- Day 1-7
- Day 8-11
- Day 12-17
- Day 18-25
- Day 26-28
- Not known

11. If you suffer from headaches, since how long have you been having headaches?

*Please give details*

12. Over the past 2 months, how many individual headache attacks have you had on average per month?

*Please give details*

13. How long does a typical headache attack last?

- 0-1 hour       >1-6 hours       >6-12 hours       >12-24 hours       >24-48 hours
- >72 hours       constant       too variable       unknown

14. Check any of the following factors which seems to trigger a headache attack in you:

- |                                       |   |  |
|---------------------------------------|---|--|
| <input type="checkbox"/> Alcohol      | <input type="checkbox"/> Odours           | <input type="checkbox"/> Changes in weather                |
| <input type="checkbox"/> Caffeine     | <input type="checkbox"/> Emotional stress | <input type="checkbox"/> Lack of routine physical activity |
| <input type="checkbox"/> Menstruation | <input type="checkbox"/> Fatigue          | <input type="checkbox"/> Other <i>Please give details</i>  |
| <input type="checkbox"/> Exercise     | <input type="checkbox"/> Missing meals    |  |

15. What other factors seem to help to relief your headache? *Please give details*

16. Are your headaches ever incapacitating? *Please, answer the questions below*

16.1. *On how many days in the last 3 months did you miss work or school because of your headaches? If you did not attend work or school write zero*

16.2. *How many days in the last 3 months was your productivity at work or school reduced by half or more because of your headaches? Do not include days you counted in question 16.1, where you did not attend work or school. If you did not attend work or school write zero.*

16.3. *On how many days in the last 3 months did you not do household work because of your headaches? Please give details*

16.4. *How many days in the last 3 months was your productivity in household work reduced by half or more because of your headaches? Do not include days you counted in question 16.3, where you did not do household work. Please give details*

16.5. *On how many days in the last 3 months did you miss family, social, or leisure activities because of your headaches? Please give details*

16.6. *On how many days in the last 3 months did you have a headache? If headache lasted more than one day, count each day*

16.7. *On a scale of 0-10, on average, how painful were these headaches? (Where 0=no pain at all and 10=pain which is as bad as it can be)*

17. How would you describe your headache?

- Throbbing/pulsating pain
- Pain over the scalp region (cutaneous allodynia)
- Mild pressure
- Unknown

18. Is your headache ever localized to one side? Yes  No  *If yes, please give details*

19. Does your headache typically occur at a certain time of day or of certain days of the week or month? Yes  No   
*If yes, please give details*

20. Do you have any warning symptoms which alert you are going to have a headache attack? Yes  No

*If yes, please give details*

21. Do you ever experience any of the following symptoms in association with your headache attacks (before, during or after)

- |  |  |
|--|--|
| <input type="checkbox"/> Nausea  | <input type="checkbox"/> Speech disturbance  |
| <input type="checkbox"/> Vomiting  | <input type="checkbox"/> Numbness and/or tingling in face, arm or leg                          |
| <input type="checkbox"/> Nasal congestion                                    | <input type="checkbox"/> Loss of balance   |
| <input type="checkbox"/> Diarrhoea   | <input type="checkbox"/> Vertigo (spinning sensation)  |
| <input type="checkbox"/> Inability to tolerate loud noise<br>(phonophobia)   | <input type="checkbox"/> Visual changes (visual distortion, flashes,<br>blind spots, sparkles) |
| <input type="checkbox"/> Inability to tolerate bright light<br>(photophobia) | <input type="checkbox"/> Visual Aurea  |
| <input type="checkbox"/> Extreme thirst, food cravings                       | <i>If visual Aurea, please give detail of duration</i>   |